CDC panel unanimously recommends Novavax Covid-19 vaccine for adults

In this photo illustration a silhouette of a man holding a medical syringe and a vial seen displayed in front of the Novavax logo on a screen.
Cezary Kowalski | Lightrocket | Getty Images

The Centers for Disease Control and Prevention’s independent advisors recommended Novavax’s two-dose Covid-19 vaccine as a primary series for adults on Tuesday, one of the final steps before pharmacies can start administering the shots.

The CDC committee voted unanimously to recommend the vaccine for people ages 18 and older after reviewing the shots’ safety and effectiveness during an hourslong public meeting Tuesday. CDC Director Dr. Rochelle Walensky could give the greenlight for vaccinations to start as soon as this week.

Novavax stock rose 12% after the CDC panel’s recommendation.

Walensky’s endorsement will complete a two-year journey for Novavax, one of the early participants in the U.S. race to produce a vaccine to protect against Covid-19. The small Maryland biotech company received $1.8 billion of taxpayer money from Operation Warp Speed, but struggled to get its manufacturing base in place and ultimately fell behind Pfizer and Moderna.

Novavax’s vaccine will enter the U.S. at a time when more than three-fourths of U.S. adults, 77%, are now fully vaccinated with Pfizer, Moderna and to a much lesser degree Johnson & Johnson’s shots, according to CDC data.

U.S. health officials and Novavax executives have said the vaccine will provide another option for people who do not want to take Pfizer and Moderna’s shots. Anywhere from 26 million to 37 million adults are still unvaccinated in the U.S., according to CDC data, but it’s unclear how many of those people will opt to take Novavax’s vaccine.

The Biden administration has secured 3.2 million doses of Novavax’s vaccine so far, according to the Health and Human Services Department.

Effectiveness and safety

Novavax’s shots were 90% effective at preventing illness overall and 100% effective at preventing severe disease when the alpha variant of Covid was dominant, according to clinical trial data. The company has not published data on the real-world effectiveness of its shots against omicron and its subvariants.

But Novavax’s vaccine appears to produce a strong immune response against omicron and its subvariants, which would suggest that it is effective against the variant. The company’s immune response data against omicron impressed members of the Food and Drug Administration’s vaccine committee last month.

The FDA in a fact sheet for health-care providers warned that Novavax’s vaccine appears to carry a risk of heart inflammation called myocarditis. FDA officials flagged four cases of myocarditis and pericarditis — swelling in a membrane surrounding the heart — from Novavax’s clinical trial in young men ages 16 to 28.

Pfizer and Moderna’s shots also pose an elevated risk of myocarditis for adolescent boys and young men after the second dose. The CDC has found that Covid infection carries a greater risk of heart inflammation than vaccination with Pfizer or Moderna’s shots. Myocarditis is typically caused by viral infections.

Different technology

Novavax’s vaccine uses a different platform than Pfizer’s and Moderna’s shots. The Novavax vaccine is based on protein technology already used in HPV and hepatitis B vaccines.

The company produces inactive copies of the virus spike protein by inserting genetic code into an insect virus that infects moth cells. The spike copies are harvested and purified from those cells for its vaccine.

The spike protein is the mechanism the virus uses to invade human cells. The spike copies in the vaccine prepare the body’s immune system to produce antibodies that block the virus from invading human cells. Novavax’s vaccine also has an additional ingredient, called an adjuvant, that is derived from the bark of a South American tree to produce a broader immune response to fight the virus.

Pfizer and Moderna’s vaccine, by contrast, use messenger RNA technology. Their shots deliver messenger RNA to human cells, which then produce inactive copies of the spike protein to generate an immune response to fight the virus. Pfizer and Moderna’s shots are the first mRNA vaccines to receive approval from the FDA.

Novavax’s shots are also stored at normal refrigerator temperatures, while Pfizer’s and Moderna’s shots require subzero cold.

Though the FDA has repeatedly authorized Pfizer’s and Moderna’s shots as safe and effective vaccines for every age group in the U.S., health officials have struggled to convince millions of skeptics to take the shots.

Fall vaccine change

The U.S. is planning to tweak the vaccines to target the more transmissible BA.4 or BA.5 omicron subvariants, which are now dominant, ahead of an expected fall vaccination campaign. The Covid vaccines are less effective at preventing infection from omicron due to the variant’s many mutations, but they are still generally protecting against severe disease.

U.S. health officials believe changing the formula of the vaccines to target omicron variants as well as the original strain that emerged in Wuhan, China in 2019 will provide more durable protection against the virus this fall.

Novavax’s vaccine, like every currently authorized Covid shot, is based on the original strain of the virus that first emerged in China. Like Pfizer and Moderna, Novavax is developing vaccines that target the omicron variant, but company executives have said it’s not clear that they need to roll out an updated shot because the company’s current vaccine triggers a broad immune response against the variant.

The CDC and the FDA have not approved mixing and matching Novavax’s vaccine with Pfizer’s and Moderna’s shots as a booster. Novavax has said it plans to ask the FDA to authorize a booster shot of its vaccine.